ESPR
$2.71
Esperion Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C) in the United States.
Recent News
Esperion Therapeutics Touts 38% Revenue Growth, Corstasis Deal and 2026 Cash-Gen Path at Conference
Executives from Esperion Therapeutics (NASDAQ:ESPR) highlighted accelerating revenue growth, plans to expand its commercial footprint, and details of a pending acquisition during remarks at the Citizens Life Sciences Conference in Miami, coming a day after the company reported earnings. 2025 result
Esperion Therapeutics Inc (ESPR) Q4 2025 Earnings Call Highlights: Record Revenue Growth and ...
Esperion Therapeutics Inc (ESPR) reports a 144% revenue surge in Q4 2025, driven by strategic partnerships and successful commercial execution.
Esperion Therapeutics Q4 Earnings Call Highlights
Esperion Therapeutics (NASDAQ:ESPR) executives told investors the company delivered its “strongest performance to date” in 2025 and is entering 2026 with what management described as strong commercial momentum, an improving balance sheet, and an agreement to acquire Corstasis Therapeutics and its ne
Esperion Therapeutics (ESPR) Misses Q4 Earnings Estimates
Esperion Therapeutics (ESPR) delivered earnings and revenue surprises of -5.38% and +4.90%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Esperion Therapeutics: Q4 Earnings Snapshot
ANN ARBOR, Mich. AP) — Esperion Therapeutics Inc. ESPR) on Tuesday reported fourth-quarter profit of $61.8 million.